Tyrosine Kinase
Receptor tyrosine kinases bind to extracellular ligands/growth factors, which promotes receptor dimerization and autophosphorylation of receptor tyrosine residues. This triggers a cascade of downstream events through phosphorylation of intracellular proteins that ultimately transduce the extracellular signal to the nucleus, causing changes in gene expression. Receptor tyrosine kinases include EGFR/ErbB, PDGFR, VEGFR, FGFR and MET subfamilies etc. Dysfunctions in tyrosine phosphorylation are linked to oncogenic transformation. In additions, various adaptor and effector proteins couple to carboxy-terminal of an active kinase. For instance, binding of the GRB2 adaptor protein activates EGFR and MAPK/ERK signaling.
Non-receptor tyrosine kinases involve many well-defined proteins (e.g. the Src family kinases, c-Abl, and Jak kinases) and other kinases which regulates cell growth and differentiation. For example, Src family kinases are curial for activating and inhibitory pathways in the innate immune response.
-
A4145 TG101209Summary: JAK2/3 inhibitor
-
A4123 KW 2449Target: Aurora Kinases|FLT3|Bcr-AblSummary: Multikinase inhibitor
-
A4237 Amuvatinib (MP-470, HPK 56)Summary: Tyrosine kinase inhibitor
-
A3194 AST 4871 CitationTarget: RETSummary: RET kinase inhibitor
-
B6097 SU5614Summary: tyrosine kinase inhibitor
-
B7853 Tandutinib (MLN518) HClSummary: FLT3 inhibitor,potent and selective
-
B5516 5'-FluoroindirubinoximeSummary: FMS-like receptor tyrosine kinase-3 (FLT3) inhibitor
-
A8889 G-749Target: Aurora Kinases|FLT3|c-RETSummary: FLT3 inhibitor
-
B8016 UNC20251 CitationTarget: MER|FLT3Summary: orally bioavailable dual MER/FLT3 inhibitor